The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.
Who can participate
Age range18 Years – 74 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study.
* Outpatients aged 18 through 74 years at the time of consent
* Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.
Exclusion Criteria:
* Patients with imminent risk of suicide or injury to self, others, or property.
* Patients who had been hospitalized because of a manic or mixed episode within 60 days prior to screening.
* Patients who are otherwise considered ineligible for the study by the investigator.
What they're measuring
1
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6